Champix Tablet

Introduction

Varenicline tartrate is a prescription medication used primarily to help people quit smoking. It is marketed under the brand name Chantix, among others. Varenicline is a partial agonist at nicotine receptors in the brain, which helps to reduce cravings and withdrawal symptoms associated with quitting smoking.

Uses

Varenicline tartrate is used for:

Smoking Cessation: To assist individuals in quitting smoking by reducing withdrawal symptoms and cravings. It is used as part of a comprehensive smoking cessation program.

Brand Name	Champix
Type	Tablet
Weight	0.5 mg
Generic	Varenicline Tartrate
Manufacturer	Janata Traders
Available in	English বাংলা

Mechanism of Action

Varenicline tartrate works by:

Partial Agonism: It binds to nicotine receptors in the brain, partially stimulating them to reduce cravings and withdrawal symptoms, while also blocking nicotine from attaching to these receptors.
Reduction of Dopamine Release: By partially stimulating nicotine receptors, it leads to a moderate release of dopamine, which helps to alleviate withdrawal symptoms without causing the high associated with nicotine.

How Long Does It Take to Work?

Varenicline typically begins to work within a week of starting treatment. Most individuals will start to notice a reduction in cravings and withdrawal symptoms within 1-2 weeks. The full benefits are usually observed after 4-6 weeks of treatment.

Absorption

Varenicline is rapidly absorbed after oral administration. Peak plasma concentrations are reached within 3-4 hours. The drug is well-absorbed with an oral bioavailability of approximately 90%.

Route of Elimination

Varenicline is primarily eliminated through the kidneys. It is excreted as unchanged drug in the urine, with approximately 92% of the dose excreted this way.

Dosage

Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided additional advice and support. Provide patients with appropriate educational materials and counseling to support the quit attempt.

The patient should set a date to stop smoking. Begin Varenicline dosing one week before this date. Alternatively, the patient can begin Varenicline dosing and then quit smoking between days 8 and 35 of treatment.

The recommended dose of Varenicline is 1 mg twice daily following a 1-week titration as follows:

Days 1-3: 0.5 mg once daily
Days 4-7: 0.5 mg twice daily
Day 8-end of treatment: 1 mg twice daily

Patients should be treated with Varenicline for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with Varenicline is recommended to further increase the likelihood of long-term abstinence.

For patients who are sure that they are not able or willing to quit abruptly, consider a gradual approach to quitting smoking with Varenicline. Patients should begin Varenicline dosing and reduce smoking by 50% from baseline within the first four weeks, by an additional 50% in the next four weeks, and continue reducing with the goal of reaching complete abstinence by 12 weeks. Continue Varenicline treatment for an additional 12 weeks, for a total of 24 weeks of treatment. Encourage patients to attempt quitting sooner if they feel ready

Patients who are motivated to quit, and who did not succeed in stopping smoking during prior Varenicline therapy for reasons other than intolerability due to adverse events or who relapsed after treatment, should be encouraged to make another attempt with Varenicline once factors contributing to the failed attempt have been identified and addressed.

Consider a temporary or permanent dose reduction in patients who cannot tolerate the adverse effects of Varenicline.

The recommended dosage of varenicline tartrate is:

Initial Dose: 0.5 mg once daily for the first 3 days.
Escalation: Increase to 0.5 mg twice daily for the next 4 days.
Maintenance Dose: 1 mg twice daily for 11-12 weeks. The treatment duration can be extended if needed, based on the individual's response.

Administration

Varenicline is administered orally in the form of tablets. It should be taken after a meal with a full glass of water to reduce the risk of gastrointestinal discomfort.

Side Effects

Common side effects include:

Nausea: The most common side effect, occurring in approximately 30% of users.
Insomnia: Difficulty sleeping or abnormal dreams.
Headache: Mild to moderate headaches.
Constipation: Some individuals may experience digestive issues.

Toxicity

Acute toxicity is rare, but overdose symptoms may include severe nausea, vomiting, agitation, and confusion. In case of overdose, seek immediate medical attention.

Precautions

Precautions include:

Psychiatric Conditions: Monitor patients with a history of psychiatric disorders, as varenicline may affect mood and behavior.
Renal Function: Use with caution in individuals with impaired renal function as dose adjustments may be necessary.

Interaction

Varenicline may interact with:

Alcohol: May increase the risk of alcohol-related side effects or impairments.
Other CNS Depressants: May enhance the effects of other central nervous system depressants.

Disease Interaction

Considerations for specific conditions include:

Severe Renal Impairment: Dose adjustment may be required in individuals with severe renal impairment.
History of Mental Health Disorders: Monitor closely for potential exacerbation of psychiatric symptoms.

Drug Interaction

Potential drug interactions include:

Nicotine Replacement Therapies: Using varenicline with other nicotine replacement therapies is generally not recommended.
Antidepressants: May interact with medications that affect mood and mental health.

Food Interactions

No significant food interactions are known. It is generally recommended to take varenicline after a meal to minimize gastrointestinal side effects.

Pregnancy Use

Varenicline is classified as a Category C drug for pregnancy. It should be used only if the potential benefits outweigh the risks. Pregnant women should consult their healthcare provider before starting treatment.

Lactation Use

It is unknown if varenicline is excreted in breast milk. Use with caution during lactation, and consult a healthcare provider for advice if breastfeeding.

Acute Overdose

Symptoms of acute overdose may include severe nausea, vomiting, confusion, or agitation. Seek medical attention immediately if an overdose is suspected.

Contraindication

Varenicline is contraindicated in:

Individuals with a History of Hypersensitivity: To varenicline or any of its components.
Severe Renal Impairment: Without dose adjustment and close monitoring.

Use Direction

Follow the prescribed dosage and administration instructions provided by a healthcare provider. It is important to adhere to the treatment plan and not to discontinue use abruptly without medical advice.

Storage Conditions

Store varenicline tablets at room temperature, away from moisture and heat. Keep out of reach of children.

Volume of Distribution

The volume of distribution of varenicline is approximately 400 liters, indicating that it is widely distributed throughout body tissues.

Half Life

The half-life of varenicline is approximately 24 hours, which allows for once-daily dosing in some cases.

Clearance

Varenicline is primarily cleared through the kidneys. The clearance rate can be affected by renal function, requiring dose adjustments in patients with impaired renal function.

See in details version Champix Tablet 0.5 mg also Champix Tablet 0.5 mg in bangla